Spiomet4Health
SPIOMET4HEALTH will test the efficacy of this new treatment for Polycystic Ovary Syndrome (PCOS) in adolescent girls and young adult women, in a multi-centric phase II clinical trial.
SPIOMET4HEALTH is the first treatment for PCOS, the most common endocrine-metabolic disorder among women of reproductive age, affecting 5-10% of women worldwide.
.jpg)
This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 899671.
Documentation
Tender for Subcontracting an online platform to store radiological images and their quantitative and qualitative analysis to study the efficacy and safety of a novel treatment (SPIOMET) for Polycystic Ovary Syndrome (PCOS) in adolescent girls and young women.
Call open to 14 January 2022
Tender for contracting a translators' agency for the Horizon 2020 funded project "Study of the efficacy and safety of a novel treatment (SPIOMET) for Polycystic Ovary Syndrome (PCOS) in adolescent girls and young women (SPIOMET4HEALTH).
Call open to July 2021